Development asset linked to GSK Glaxo Smith in public FDA and regional records.
pharma · Asthma · Respiratory Syncytial Virus Infections
GSK Glaxo Smith
GlaxoSmithKline
GSK Glaxo Smith drug portfolio — 143 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX HQ
30 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
- Employees
- 30
- Programs
- 4
- Drugs
- 143
- Patents
- 0
GSK Glaxo Smith pipeline
Portfolio lens on 143 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
GSK Glaxo Smith drug portfolio — 143 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
adefovir dipivoxil
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA polymerase/reverse transcriptase.
- Target
- DNA polymerase/reverse transcriptase
- Mechanism
- DNA polymerase/reverse transcriptase inhibitor
-
albiglutide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Interleukin-2 receptor.
- Target
- Interleukin-2 receptor
- Mechanism
- Interleukin-2 receptor agonist
-
allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 3A.
- Target
- 5-hydroxytryptamine receptor 3A
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records.
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in GSK Glaxo Smith's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
aprepitant
Alimentary tract and metabolism (A04)US regulatory status: approved. Molecular target: Substance-P receptor.
- Target
- Substance-P receptor
- Mechanism
- Neurokinin 1 receptor antagonist
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
belantamab mafodotin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tumor necrosis factor receptor superfamily member 17 binding agent
-
US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
belimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor ligand superfamily member 13B.
- Target
- Tumor necrosis factor ligand superfamily member 13B
- Mechanism
- Tumor necrosis factor ligand superfamily member 13B inhibitor
-
benralizumab
Respiratory system (R03)US regulatory status: approved. Molecular target: Interleukin-5 receptor subunit alpha.
- Target
- Interleukin-5 receptor subunit alpha
- Mechanism
- Interleukin-5 receptor subunit alpha inhibitor
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
bortezomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
budesonide
Alimentary tract and metabolism (A07)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved.
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
carfilzomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records. Molecular target: Substance-P receptor.
- Target
- Substance-P receptor
- Mechanism
- Neurokinin 1 receptor antagonist
-
characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
Musculo-skeletal system (M09)Musculo-skeletal system (M09) compound in GSK Glaxo Smith's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
US regulatory status: approved. Molecular target: Ferriprotoporphyrin IX.
- Target
- Ferriprotoporphyrin IX
- Mechanism
- Ferriprotoporphyrin IX binding agent
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
US regulatory status: approved.
-
covid-19 mrna vaccine
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Molecular target: Spike glycoprotein.
- Target
- Spike glycoprotein
- Mechanism
- Spike glycoprotein vaccine antigen
-
dabrafenib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Mechanism: Serine/threonine-protein kinase B-raf inhibitor.
- Mechanism
- Serine/threonine-protein kinase B-raf inhibitor
-
daprodustat
Blood and blood forming organs (B03)US regulatory status: approved. Molecular target: Hypoxia-inducible factor prolyl hydroxylase.
- Target
- Hypoxia-inducible factor prolyl hydroxylase
- Mechanism
- Hypoxia-inducible factor prolyl hydroxylase inhibitor
-
daratumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
- Target
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
- Mechanism
- Lymphocyte differentiation antigen CD38 inhibitor
-
denosumab
Musculo-skeletal system (M05)US regulatory status: approved. Molecular target: Tumor necrosis factor ligand superfamily member 11.
- Target
- Tumor necrosis factor ligand superfamily member 11
- Mechanism
- Tumor necrosis factor ligand superfamily member 11 inhibitor
-
depemokimab
Respiratory system (R03)Respiratory system (R03) compound in GSK Glaxo Smith's portfolio. Molecular target: Interleukin-5.
- Target
- Interleukin-5
- Mechanism
- Interleukin-5 inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
dexamethasone phosphate
Systemic hormonal preparations (H02)Systemic hormonal preparations (H02) compound in GSK Glaxo Smith's portfolio.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio.
-
diphtheria (d), tetanus (t), pertussis (whole cell) (pw) and hepatitis b (rdna) (hbv) vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio.
-
diphtheria, tetanus, acellular pertussis and hepatitis b recombinant, adsorbed vaccine
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio.
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
dostarlimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 antagonist
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records. Molecular target: Envelope glycoprotein E.
- Target
- Envelope glycoprotein E
- Mechanism
- Envelope glycoprotein E vaccine antigen
-
US regulatory status: approved. Molecular target: Steroid 5-alpha-reductase.
- Target
- Steroid 5-alpha-reductase
- Mechanism
- Steroid 5-alpha-reductase inhibitor
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records.
-
eltrombopag
Blood and blood forming organs (B02)US regulatory status: approved. Mechanism: Thrombopoietin receptor agonist.
- Mechanism
- Thrombopoietin receptor agonist
-
US regulatory status: approved. Molecular target: Thrombopoietin receptor.
- Target
- Thrombopoietin receptor
- Mechanism
- Thrombopoietin receptor agonist
-
enzalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: KCNQ (Kv7) potassium channel.
- Target
- KCNQ (Kv7) potassium channel
- Mechanism
- KCNQ (Kv7) potassium channel opener
-
florbetaben (18f)
Various (V09)Various (V09) compound in GSK Glaxo Smith's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records.
-
fluticasone furoate
Respiratory system (R03)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records.
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records.
-
formoterol
Respiratory system (R03)Respiratory system (R03) compound in GSK Glaxo Smith's portfolio. Mechanism: Beta-2 adrenergic receptor agonist.
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Sulfonylurea receptor 1, Kir6.2.
- Target
- Sulfonylurea receptor 1, Kir6.2
- Mechanism
- Sulfonylurea receptor 1, Kir6.2 blocker
-
herpes zoster vaccine (recombinant, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Molecular target: Envelope glycoprotein E.
- Target
- Envelope glycoprotein E
- Mechanism
- Envelope glycoprotein E vaccine antigen
-
human heterologous liver cells
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in GSK Glaxo Smith's portfolio.
-
human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio.
-
insulin glargine
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
insulin human
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
isatuximab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
- Target
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
- Mechanism
- Lymphocyte differentiation antigen CD38 inhibitor
-
lamivudine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
lapatinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Mechanism: Receptor protein-tyrosine kinase erbB-2 inhibitor.
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
lenalidomide
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase inhibitor
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records.
-
luspatercept
Blood and blood forming organs (B03)Blood and blood forming organs (B03) compound in GSK Glaxo Smith's portfolio. Molecular target: Transforming growth factor beta.
- Target
- Transforming growth factor beta
- Mechanism
- Transforming growth factor beta inhibitor
-
US regulatory status: approved. Molecular target: Transforming growth factor beta.
- Target
- Transforming growth factor beta
- Mechanism
- Transforming growth factor beta inhibitor
-
US regulatory status: approved. Molecular target: Acetylcholinesterase.
- Target
- Acetylcholinesterase
- Mechanism
- Acetylcholinesterase inhibitor
-
meningococcal group b vaccine (rdna, component, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio.
-
meningococcal groups a, c, w-135 and y conjugate vaccine
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Mechanism: Immunostimulant.
- Mechanism
- Immunostimulant
-
mepolizumab
Respiratory system (R03)US regulatory status: approved. Molecular target: Interleukin-5.
- Target
- Interleukin-5
- Mechanism
- Interleukin-5 inhibitor
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records. Molecular target: Tyrosine-protein kinase JAK1.
- Target
- Tyrosine-protein kinase JAK1
- Mechanism
- Tyrosine-protein kinase JAK1 inhibitor
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records. Mechanism: Cysteinyl leukotriene receptor 1 antagonist.
- Mechanism
- Cysteinyl leukotriene receptor 1 antagonist
-
US regulatory status: approved. Molecular target: Isoleucine--tRNA ligase.
- Target
- Isoleucine--tRNA ligase
- Mechanism
- Isoleucyl-tRNA synthetase inhibitor
-
Various (V04) compound in GSK Glaxo Smith's portfolio.
-
niraparib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Molecular target: Poly [ADP-ribose] polymerase 2.
- Target
- Poly [ADP-ribose] polymerase 2
- Mechanism
- Poly [ADP-ribose] polymerase-1 inhibitor
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records. Molecular target: Poly [ADP-ribose] polymerase 2.
- Target
- Poly [ADP-ribose] polymerase 2
- Mechanism
- Poly [ADP-ribose] polymerase 2 inhibitor
-
nirogacestat
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Molecular target: Gamma-secretase.
- Target
- Gamma-secretase
- Mechanism
- Gamma-secretase inhibitor
-
orlistat
Alimentary tract and metabolism (A08)US regulatory status: approved. Molecular target: Gastric triacylglycerol lipase.
- Target
- Gastric triacylglycerol lipase
- Mechanism
- Pancreatic lipase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
pandemic influenza vaccine (h5n1) (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
pazopanib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Mechanism: Vascular endothelial growth factor receptor inhibitor.
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records.
-
pioglitazone
Alimentary tract and metabolism (A10)Alimentary tract and metabolism (A10) compound in GSK Glaxo Smith's portfolio. Mechanism: Peroxisome proliferator-activated receptor gamma agonist.
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor gamma.
- Target
- Peroxisome proliferator-activated receptor gamma
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Mechanism: Immunostimulant.
- Mechanism
- Immunostimulant
-
pneumococcal saccharide conjugated vaccine, adsorbed
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Mechanism: Immunostimulant.
- Mechanism
- Immunostimulant
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
pomalidomide
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Molecular target: Fusion glycoprotein F0.
- Target
- Fusion glycoprotein F0
- Mechanism
- Fusion glycoprotein F0 vaccine antigen
-
retigabine
Nervous system (N03)Nervous system (N03) compound in GSK Glaxo Smith's portfolio. Molecular target: KCNQ (Kv7) potassium channel.
- Target
- KCNQ (Kv7) potassium channel
- Mechanism
- KCNQ (Kv7) potassium channel opener
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records. Mechanism: Vascular endothelial growth factor receptor 2 inhibitor.
- Mechanism
- Vascular endothelial growth factor receptor 2 inhibitor
-
rosiglitazone
Alimentary tract and metabolism (A10)Alimentary tract and metabolism (A10) compound in GSK Glaxo Smith's portfolio. Molecular target: Peroxisome proliferator-activated receptor gamma.
- Target
- Peroxisome proliferator-activated receptor gamma
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
rotavirus vaccine
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
rotavirus vaccine, live
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records.
-
salmeterol
Respiratory system (R03)Respiratory system (R03) compound in GSK Glaxo Smith's portfolio. Mechanism: Beta-2 adrenergic receptor agonist.
- Mechanism
- Beta-2 adrenergic receptor agonist
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records.
-
shingles (herpes zoster) vaccine (live)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in GSK Glaxo Smith's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved.
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records. Mechanism: Adrenergic receptor alpha-1 antagonist.
- Mechanism
- Adrenergic receptor alpha-1 antagonist
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
topotecan
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in GSK Glaxo Smith's portfolio. Mechanism: DNA topoisomerase I, mitochondrial inhibitor.
- Mechanism
- DNA topoisomerase I, mitochondrial inhibitor
-
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I, mitochondrial inhibitor
-
ulipristal acetate
Genito-urinary system and sex hormones (G03)US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor modulator
-
umeclidinium
Respiratory system (R03)Respiratory system (R03) compound in GSK Glaxo Smith's portfolio. Mechanism: Muscarinic acetylcholine receptor M3 antagonist.
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to GSK Glaxo Smith in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
zanamivir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Neuraminidase.
- Target
- Neuraminidase
- Mechanism
- Neuraminidase inhibitor